# The Protective Effect of Tetrahydrobiopterin on the Nitric Oxide-Mediated Inhibition of Purified Nitric Oxide Synthase

Jinjoo Hyun<sup>1</sup>, Yumiko Komori<sup>1</sup>, Gautam Chaudhuri<sup>1,2</sup>, Louis J. Ignarro<sup>1</sup> and Jon M. Fukuto<sup>1\*</sup>

<sup>1</sup>Department of Pharmacology and <sup>2</sup>Department of Obstetrics and Gynecology, UCLA School of Medicine, Center for the Health Sciences, Los Angeles, California 90024-1735

Received November 28, 1994

SUMMARY: The nitric oxide synthases (NOS) are a class of enzymes responsible for the generation of NO via an oxygen and NADPH dependent oxidation of the amino acid arginine. These enzymes are ironheme proteins which contain FAD and FMN and, enigmatically, require tetrahydrobiopterin (BH4). NOS has recently been shown to be subject to inhibition by its product, NO. Preliminary data by us indicate that a possible role for BH4 is to prevent and/or reverse the NO-mediated inhibition of NOS. The objective of this study was to elucidate the mechanism by which BH4 protects NOS against NO inhibition. Protection of NOS from NO inhibition was observed by both BH4 and the BH4 regeneration system, dihydropteridine reductase (DHPR)/NADH. NO, rather than an oxidation product, appears to be the inhibitory species. Protection by BH4 is not likely due to a simple chemical reaction between BH4 and NO or its oxidation product, NO2. The results are consistent with a protective mechanism by which BH4 may act as a nonstoichiometric reducing agent for a redox active enzyme component, such as the ironheme, to prevent NO ligation.

© 1935 Academic Press, Inc.

The catalytic conversion of arginine to nitric oxide (NO) and citrulline is performed by a class of enzymes generally referred to as the nitric oxide synthases (NOS). The physiological relevance of this process has been reviewed [for example, see 1, 2]. Analogous to the more well characterized cytochrome P450 enzyme systems (P450), NOS is an ironheme protein [3, 4, 5, 6] which utilizes NADPH and molecular oxygen and requires FAD and FMN [7]. One of the outstanding features of NOS which distinguishes it from P450, however, is its requirement for tetrahydrobiopterin (BH<sub>4</sub>) [for example, 8, 9, 10]. Although the requirement for BH<sub>4</sub> for maximal catalytic activity is well established, the specific role of BH<sub>4</sub> in NOS catalysis is not very clear. Giovanelli and coworkers suggested that BH<sub>4</sub> may not have a stoichiometric role in NOS catalysis and may be acting as an allosteric modulator or may function to protect NOS by keeping a crucial catalytic component in the reduced state [11]. Hevel and Marletta have proposed a likely redox role for BH<sub>4</sub> in macrophage NOS catalysis and did not rule out the

<u>Abbreviations</u>: NOS, nitric oxide synthase; NO, nitric oxide; BH<sub>4</sub>, tetrahydrobiopterin; DHPR, dihydropteridine reductase; P450, cytochrome P450.

<sup>\*</sup>To whom correspondence should be addressed. FAX: 310 825 6267.

possibility that BH<sub>4</sub> may reactivate the NOS after an occasional inactivation event during turnover [10]. More recently, we have proposed that BH<sub>4</sub> may be involved in the protection of NOS from inhibition by its product, NO [12] and thus may be utilized in a redox and nonstoichiometric fashion. The purpose for this study was to further evaluate the protective action of BH<sub>4</sub> on NOS inhibition by NO and to elucidate the mechanism of this protective effect.

### MATERIALS AND METHODS

Chemicals and Solutions: EDTA, EGTA, L-ascorbic acid, glycerol, pepstatin A, leupeptin, phenylmethylsulfonyl fluoride, dithiothreitol, FAD, NADP+, NADPH, L-arginine, calmodulin, L-citrulline, NADH, dihydropteridine reductase, DEAE Sephacel, and Trizma Base were purchased from Sigma Chemical Co. (St. Louis, MO). Tetrahydrobiopterin was purchased from Schircks laboratories (Jona, Switzerland). 2',5'-ADP Sepharose 4B was obtained from Pharmacia (Milwaukee, WI). NO gas (Matheson Gas Products, Cucamunga, CA) was passed through basic water before use to trap any nitrogen dioxide (NO<sub>2</sub>) impurity. NO<sub>2</sub> gas (Matheson) was used directly from the tank. Aqueous solutions of NO were obtained by bubbling 70-100 mL of pure NO gas through 5 mL of degassed buffer contained in a Schlenk tube sealed with a rubber septum. The concentration of the NO solution was approximately 2 mM as determined by sparging the gaseous contents of a 1 mL sample into a chemiluminescence detector (Antek 720) with a nitrogen stream. Quantitation of the sparged NO was accomplished by comparison to a standard curve based on the detector response from injections of authentic NO. Dowex AG50W-X8 (H<sup>+</sup> form), 100-200 mesh and Dowex AG 1-X8 (acetate form), 100-200 mesh were purchased from Bio-Rad Laboratories. Aquasol-2 was purchased from Du Pont Company/NEN Research Products.

Purification of NOS: The purification of rat brain NOS was accomplished using a modification of the procedure of Bredt and Snyder [13] and has been described previously [14].

Protein Determination: Protein concentrations were determined using the Bradford, Coomassie blue method described by Bio Rad laboratories (Hercules, CA). Bovine serum albumin (Pierce, Rockford, IL) was used as the standard.

Assay of NOS Activity: NOS activity was measured using the method of Bredt and Snyder [15] which monitors the conversion of [³H]arginine to [³H]citrulline and has been utilized and described previously by us [14]. Enzymatic reactions were initiated by addition of the reaction cofactors and substrates to buffer solution containing NOS. Incubations carried out in the presence of exogenously added NO or NO2 were performed in the usual way with the following modifications. NO was added to the incubation by simply adding an NO-buffer solution, of known concentration (see above), to the mixture containing NOS immediately after the addition of the reaction cofactors (including the appropriate concentration of BH4) and substrates. NO2 was added to the incubation by adding a diluted mixture of NO2 in air, via a gastight syringe, into the incubation mixture containing NOS immediately after the addition of the reaction cofactors and substrates. In studies examining the effects of ascorbate or DHPR, addition of ascorbate or DHPR/NADH (100 µM final concentration) solutions to the incubation mixture was performed just after the addition of NOS. In all cases, control incubations contained only vehicle.

Reaction of BH<sub>4</sub> with NO and NO<sub>2</sub>: A possible reaction between NO and BH<sub>4</sub> was examined by both observing possible changes in the optical spectrum of BH<sub>4</sub> in the presence of NO and by monitoring NO loss in the presence of BH<sub>4</sub> by chemiluminescence detection. In the chemiluminescence experiment,  $100 \, \mu L$  of NO gas (4.5  $\mu$ mol) was injected, using a gastight syringe, into each of two 10 mL round bottomed flasks which had been degassed with nitrogen and sealed with a gastight rubber septum. Into one flask was then injected 2 mL of degassed  $100 \, \mu L$  mM phosphate buffer, pH 7.4. Into the other flask was injected 2 mL of degassed buffer containing 2 mg of BH<sub>4</sub> (6.4  $\mu$ mol). Both solutions were then stirred for 20 minutes.  $100 \, \mu L$  aliquots of the headspace from these reactions were then examined for NO using the chemiluminescence detector. Samples were reexamined after 1 hr. In experiments using UV spectroscopy to monitor BH<sub>4</sub>, degassed solutions of BH<sub>4</sub> under nitrogen were made up in septum sealed quartz cuvettes. Spectra were then recorded on a Uvicon 810 (San Diego, CA) double beam spectrophotometer with buffer in the reference cuvette. Samples were scanned from 240-340 nm. Introduction of NO, NO<sub>2</sub> and other gasses was accomplished by injection through the

septum using gastight syringes. Rate data for the loss of BH<sub>4</sub> was obtained by monitoring the decrease in absorbance at 297 nm.

#### RESULTS

Protection of NO-mediated inhibition of NOS by BH<sub>4</sub>: As previously reported, NO was capable of inhibiting NOS activity [12, 16-20]. The activity of purified rat cerebellar NOS was typically inhibited 70-90% by 10-50 μM NO in the presence of 10 μM BH<sub>4</sub> in reaction mixture (data not shown). However, the addition of 50-500 μM BH<sub>4</sub> to the incubation mixture protected, in a concentration dependent manner, against inhibition by NO. In fact, in the presence of 500 μM BH<sub>4</sub>, NO inhibition of NOS was almost abolished. Also, under these conditions, BH<sub>4</sub> had no significant effect on control NOS activity (**Figure 1**). Significantly, another reducing agent, ascorbate, did not offer any protection against NOS inhibition by NO even when used at 2 mM concentrations (data not shown).

Protection of NO-mediated inhibition of NOS by DHPR/NADH: BH4 is known to be unstable with respect to autoxidation by molecular O<sub>2</sub>. That is, BH<sub>4</sub> can react with oxygen to give, initially, the quinoid dihydrobiopterin (q-BH<sub>2</sub>) which tautomerizes to 7,8 dihydrobiopterin (BH<sub>2</sub>) [21]. Thus, in the previous experiments, the concentration of BH<sub>4</sub> is likely to be decreasing throughout the incubation period with a subsequent buildup of oxidized BH<sub>4</sub> species such as q-BH<sub>2</sub> and BH<sub>2</sub>. One way to keep BH<sub>4</sub> in the reduced state during the NOS incubation is to add dihydropteridine reductase (DHPR) and NADH to the incubation mixture. That is, any q-BH<sub>2</sub> formed from the autoxidation of BH<sub>4</sub> can be converted back to BH<sub>4</sub> thus maintaining a higher steady-state concentration of BH<sub>4</sub>. The addition of DHPR/NADH with 10 μM BH<sub>4</sub> increased the activity of NOS to 115-157 % of control in the absence of NO (**Figure 2**). When 1




Figure 1. Protective effect of BH<sub>4</sub> on the inhibitory action of  $10\,\mu\text{M}$  NO on purified cerebellar NOS activity. Values represent the mean  $\pm$  S.E. of duplicate experiments from two separate experiments. \*p < 0.001 compared to the corresponding control.

Figure 2. Protective effect of dihydropteridine reductase (DHPR) on inhibitory action of  $50 \,\mu M$  NO on NOS Activity. Values are expressed as the mean  $\pm$  S.D. from 3 separate experiments. \*p < 0.001 compared to the corresponding control.

unit of DHPR, 200  $\mu$ M NADPH, and 10  $\mu$ M BH4 were added before the addition of NO, the inhibitory action of NO was reduced from 99% to 80%. 3.08 units of DHPR, added before the addition of NO, further reduced the NO-mediated inhibition to 48%. Thus, the addition of DHPR/NADH (to an incubation containing 10  $\mu$ M BH<sub>4</sub>) had a similar effect to adding high concentrations of BH<sub>4</sub> (50  $\mu$ M).

Reaction between NO, NO<sub>2</sub> and BH<sub>4</sub>: The possible reaction between NO and BH<sub>4</sub> was then examined. Using chemiluminescence detection for NO, it was found that addition of a degassed aqueous solution of BH<sub>4</sub> to a flask containing NO in nitrogen did not result in a decrease in measurable NO levels even after 1 hour. The possible reaction between BH<sub>4</sub> and NO (and NO-related species) was also examined by monitoring changes in the ultraviolet spectrum of BH<sub>4</sub> under a variety of conditions. Under anaerobic conditions, the spectrum of BH<sub>4</sub> remained unchanged over 10 minutes. The addition of O<sub>2</sub>, however, resulted in BH<sub>4</sub> oxidation as evidenced by a decrease in absorbance at 297 nm [22]. Further addition of approximately 4 equivalents of NO to the aerobic solution accelerated the rate of BH<sub>4</sub> loss by approximately 5-fold. However, BH<sub>4</sub> in degassed buffer remained unchanged when exposed to 4 equivalents of NO. The addition of 2 equivalents of O<sub>2</sub> to this system then resulted in a rapid loss of BH<sub>4</sub>. These results indicate that BH<sub>4</sub> does not react directly with NO but will react with a product of NO autoxidation. Moreover, the addition of 8 equivalents of NO<sub>2</sub> to an anaerobic BH<sub>4</sub> solution also resulted in a rapid decline in BH<sub>4</sub> similar to that observed in the previous experiment with NO and oxygen (these results are summarized in Table 1).

Inhibition of NOS by NO<sub>2</sub> and effect of BH<sub>4</sub>: It is well known that NO reacts readily with molecular oxygen to, eventually, generate NO<sub>2</sub>. Thus, the possible inhibition of NOS by NO<sub>2</sub> was examined. NO<sub>2</sub> was able to inhibit NOS activity at extremely high initial concentrations. However, at initial concentrations of NO<sub>2</sub> equivalent to those concentrations of NO which caused significant inhibition, no change in NOS activity was observed (**Figure 3**). For example, NO was

Table 1: Relative rates of BH4 decomposition

	Conditions	Relative rate of BH <sub>4</sub> loss <sup>1</sup>
1.	0.5 mM BH <sub>4</sub> (anaerobic)	no reaction <sup>2</sup>
2.	$0.5~\mathrm{mM~BH_4(anaerobic)} + \mathrm{O_2(2~equiv.)^3}$	1
3.	$(2) + NO (4 \text{ equiv.})^3$	5.4
4.	$0.5 \text{ mM BH}_4 \text{ (anaerobic)} + \text{NO (4 equiv.)}^3$	no reaction <sup>2</sup>
5.	$(4) + O_2 (2 \text{ equiv.})^3$	3.2
6.	$0.5 \text{ mM BH}_4 \text{ (anaerobic)} + \text{NO}_2 \text{ (8 equiv.)}^3$	4.5

<sup>&</sup>lt;sup>1</sup> Rates of BH<sub>4</sub> loss determined by measuring the decrease in absorbance at 297 nm [22] after 10 minutes.

<sup>&</sup>lt;sup>2</sup> No significant decrease in the absorbance at 297 nm observed after 10 minutes.

<sup>&</sup>lt;sup>3</sup> Addition performed by introduction of the appropriate amount of the pure gas into the cuvette via gastight syringe. Equivalents based on BH<sub>4</sub>.




Figure 3. Effects of  $NO_2$  and DHPR on NOS activity. Values represent the averages  $\pm$  S.D. from 3 separate experiments.

found to inhibit NOS activity by 99% at a 50  $\mu$ M initial concentration. However, at a 50  $\mu$ M initial NO<sub>2</sub> concentration, no loss of activity, versus control, was observed. Moreover, at the initial concentrations of NO<sub>2</sub> that did result in inhibition of NOS activity (0.5 mM), no protection by DHPR/NADH was observed.

## DISCUSSION

The inhibition of NOS by its product, NO, was first demonstrated by Rogers and Ignarro [16] and has been confirmed thereafter [17-20]. This inhibition may occur by a direct interaction between NO and the iron heme of NOS [12]. Significantly, cytochrome P450, a heme protein with reported similarity to NOS [for example see, 3], has also been shown to be inhibited by NO [23] (although the mechanism of inhibition has not been elucidated). It is also possible that NO may react with thiol groups or other amino acid side chains or prosthetic groups in NOS. For example, adenylyl cyclase was shown to lose calmodulin-mediated stimulation when NO was added, via a proposed oxidation of vicinal thiols in the enzyme [24].

In this study, 10 µM-50 µM NO inhibited the activity of purified rat cerebellar NOS by 70-99% in the presence of 10 µM BH<sub>4</sub> in the reaction mixture. However, the addition of 50-500 µM BH<sub>4</sub> produced concentration-dependent protection of the enzyme from NO-mediated inhibition. This protective effect does not appear to be a general phenomenon of reducing agents since ascorbate was unable to offer any protection and it was previously demonstrated that a large excess of NADPH also had no protective effect [12]. Since BH<sub>4</sub> is unstable with respect to oxygen, these results may indicate that the higher overall BH<sub>4</sub> concentrations, resulting from the higher initial concentrations, were responsible for the observed protection. If this were the case, it would be expected that a BH<sub>4</sub> regenerating system would also exhibit protective effects since it would maintain higher steady state BH<sub>4</sub> levels. This was indeed observed as a regenerating system consisting of DHPR/NADH was also able to attenuate the inhibitory action of NO in concentration-dependent manner.

The mechanism by which BH<sub>4</sub> protects NOS from NO-mediated inhibition is not entirely clear. Several hypotheses for the observed effect can be put forth, however. For example, it is possible that free BH<sub>4</sub> is simply acting as a scavenger for NO. However, this seems unlikely since we have shown that a direct reaction between NO and BH<sub>4</sub> does not occur. It is also possible that an NO oxidation product is the actual NOS inhibitor and that BH<sub>4</sub> is simply scavenging that inhibitory species. For example, since NO is converted to NO<sub>2</sub>, *via* air oxidation (reaction 1 and 2 below), it is possible that NO<sub>2</sub> is inhibitory and BH<sub>4</sub> protects NOS by scavenging this species.

- 1) NO +  $O_2 \Leftrightarrow \cdot OONO$
- 2)  $\cdot$ OONO + NO  $\Rightarrow$  2NO<sub>2</sub>
- 3)  $2NO_2(N_2O_4) + H_2O \Rightarrow NO_2^- + NO_3^- + 2H^+$
- 4)  $NO_2 + NO \Leftrightarrow N_2O_3$
- 5)  $N_2O_3 + H_2O \Rightarrow 2NO_2^- + 2H^+$

Also, since we have found that BH<sub>4</sub> will rapidly react with both NO<sub>2</sub> and air oxidized NO (which presumably produces NO<sub>2</sub> as an initial product), the chemistry for such a protective mechanism appears reasonable (**Table 1**). However, we have found that NO<sub>2</sub> is not a good inhibitor of NOS (requiring initial concentrations in excess of  $100 \,\mu\text{M}$ ) and whatever NOS inhibition does occur at high initial NO<sub>2</sub> concentrations was not protected against by DHPR. Thus, it is likely that the observed protection by BH<sub>4</sub> against NO-mediated NOS inhibition was not due to scavenging of NO<sub>2</sub>. The inhibition by NO<sub>2</sub> observed at high concentrations was most likely due to nonspecific destruction of NOS and was unrelated to the observed inhibitory effect of NO. Other NO oxidation products such as NO<sub>2</sub><sup>-</sup> and NO<sub>3</sub><sup>-</sup> (from reactions 3, 4 and 5 above) have been shown not to inhibit NOS and are thus are not involved [12]. Certainly other transient NO oxidation products such as N<sub>2</sub>O<sub>3</sub> (from reaction 4 above) may play a role in NOS inhibition. However, this appears unlikely since low concentrations of added NO<sub>2</sub>, which would trap any NO generated by the enzyme and presumably raise N<sub>2</sub>O<sub>3</sub> levels in the incubation mixture, did not inhibit NOS activity.

The possible role of BH<sub>4</sub> in NOS catalysis has been not been fully elucidated. It has been postulated that it could have a redox role [10] or serve as an allosteric modulator [11, 25]. Herein, we report that BH<sub>4</sub> is capable of protecting NOS against inhibition by its product, NO. Whether this phenomenon is physiologically relevant remains to be determined. The protection afforded NOS by BH<sub>4</sub> in these *in vitro* studies appears to be a direct result of an interaction between BH<sub>4</sub> and the inhibitory NOS-NO species. It has been postulated that NO can inhibit NOS by ligating the catalytic heme function forming an iron-nitrosyl complex. Thus, it is possible that BH<sub>4</sub> is capable of reducing off the inhibitory NO ligand which would result in a regeneration of active enzyme. This would therefore predict that BH<sub>4</sub> would have a non-stoichiometric redox role and that BH<sub>4</sub> was intimately coupled to the redox chemistry of the iron heme. Alternatively, as has been suggested previously, BH<sub>4</sub> may serve to keep a catalytic component of NOS reduced [11] and, possibly prevent the inhibitory actions of NO [12]. In this

scenario, BH<sub>4</sub> would be preventing NO inhibition as opposed to reversing it. Finally, BH<sub>4</sub> may be capable of reducing a nonheme NO-NOS species to regenerate the active enzyme. Again, this would be a non-stoichiometric redox role for BH4. These and other possibilities are currently under investigation. In conclusion the present study confirms the previous observation that BH<sub>4</sub> is capable of protecting against NO-mediated inhibition of NOS. Moreover, we show that the observed protection is unique to BH<sub>4</sub> and a likely result of an action against NO itself rather than an action against a product from NO autoxidation.

Acknowledgments: This work was supported by grants HL-43688 (JMF), HL-40922 (LJI), HL-35016 (LJI) and HL-46843 (GC) from the National Institute of Health.

#### REFERENCES

- Moncada, S., Palmer, R. M. J. and Higgs, E. A. (1991) Pharmacol. Rev., 43, 109-141. 1.
- Nathan, C. (1992) FASEB J., 6, 3051-3064. 2,
- 3.
- White, K. A. and Marletta, M. A., (1992) *Biochemistry* 31(29), 6627-6631. Stuehr, D. J. and Ikeda-Saito, M. (1992) *J. Biol. Chem.*. 267(29), 20547-20550. 4.
- McMillan, K., Bredt, D. S., Hirsch, D. J., Snyder, S. H., Clark, J. E. and Masters, B. S. S. 5. (1992) Proc. Natl. Acad. Sci., USA. 89, 11141-11145.
- Klatt, P., Schmidt, K. and Mayer, B. (1992) Biochem. J. 288, 15-17. 6.
- Stuehr, D. J. and Griffith, O. W. (1992) Adv. Enzymol., 65, 287-346.
- Kwon, N. S., Nathan, C. F. and Stuehr, D. J. (1989) J. Biol. Chem. 264(34), 20496-8. 20501.
- 9. Mayer, B., John, M., Heinzel, B., Werner, E. R., Wachter, H., Schultz, G. and Böhme, E. (1991) FEBS Lett. 288(1,2), 187-191.
- Hevel, J. M. and Marletta, M. A. (1992) Biochemistry 31, 7160-7165. 10.
- Giovanelli, J., Campos, K. L. and Kaufman, S. (1991) Proc. Natl. Acad. Sci. USA 88, 11. 7091-7095.
- 12. Griscavage, J. M, Fukuto, J. M., Komori, Y. and Ignarro, L. J. (1994) J. Biol. Chem., 269(34), 21644-21649.
- Bredt, D. and Snyder, S. (1990) Proc. Natl. Acad. Sci. USA 87, 682-685. 13.
- 14. Komori, Y., Chiang, K. T. and Fukuto, J. M., (1993) Arch. Biochem. Biophys., 307(2), 311-315.
- 15. Bredt, D, and Snyder, S. (1989) Proc. Natl. Acad. Sci. USA 86, 9030-9033.
- Rogers, N. E. and Ignarro, L. J. (1992) Biochem. Biophys. Res. Commun. 189, 215-234. 16.
- 17. Buga G. M., Griscavage, J. M., Rogers, N. E. and Ignarro, L. J. (1993) Circ. Res. 73, 808-812.
- 18. Griscavage, J. M., Rogers, N. E., Sherman, M. P. and Ignarro, L. J. (1993) J. Immunol. 151, 6329-6337
- 19. Assreuy, J., Cunha, I. Q., Liew, F. Y. and Moncada, S. (1993) Br. J. Pharmacol. 108, 833-837.
- 20. Rengasamy, A. and Johns, R. A. (1993) Mol. Pharmacol., 44, 124-128.
- Blair, J. A. and Pearson, A. J. (1974) *J. Chem. Soc.*, *Perkin Trans. II*, 1786-1787. Pfleiderer, W. (1984) "Folates and Pterins, Chapter 2", Blakely, R. L. and Benkovic, S. J. 22. eds., Wiley and Sons, New York, 43-114.
- Wink, D. A., Osawa, Y., Darbyshire, J. F., Jones, C. R., Eshenaur, S. C. and Nims, R. 23. W.(1993) Arch. Biochem. and Biophys. 300(1), 115-123.
- 24. Duhe, R. J., Nielsen, M. D., Dittman, A. H., Villacres, E. C., Choi, E. and Storm, D. R. (1994) J. Biol. Chem. 269(10), 7290-7296.
- Baek, K. J., Thiel, B. A., Lucas, S. and Stuehr, D. J. (1993) J. Biol. Chem., 268(28), 25. 21120-21129.